20/20 Biolabs (NASDAQ:AIDX) reported quarterly losses of $(0.26) per share which missed the analyst consensus estimate of $(0.06) by 333.33 percent. This is a 52.94 percent decrease over losses of $(0.17) per share from the same period last year. The company reported quarterly sales of $730.571 thousand which missed the analyst consensus estimate of $891.000 thousand by 18.01 percent. This is a 36.54 percent increase over sales of $535.060 thousand the same period last year.